Zelluna ASA 2024 SR
The report outlines Zelluna's ESG performance for 2024, focusing on its transition as a clinical-stage biotechnology company following a business combination. Key highlights include the implementation of the Norwegian Transparency Act, zero reported whistleblower incidents, and a commitment to the 3 Rs standard in animal research. The company reported low environmental impact with 1.0 tonne of Scope 2 emissions and 3.0 tonnes of waste. Governance structures were updated to include an ESG Committee within the Audit Committee to oversee sustainability initiatives and risk management.
Company: Zelluna ASA
Sector: Health Care
Country: Norway
Year: 2024
Type: SR
Pages: 11
Zelluna ASA
ESG Report
The report outlines Zelluna's ESG performance for 2024, focusing on its transition as a clinical-stage biotechnology company following a business combination. Key highlights include the implementation of the Norwegian Transparency Act, zero reported whistleblower incidents, and a commitment to the 3 Rs standard in animal research. The company reported low environmental impact with 1.0 tonne of Scope 2 emissions and 3.0 tonnes of waste. Governance structures were updated to include an ESG Committee within the Audit Committee to oversee sustainability initiatives and risk management.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Employees